… The efficacy of EGFR-tyrosine kinase inhibitors (TKIs) was retrospectively evaluated in patients
… The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (…

… In the present study, we used the ARMS method, which has a sensitivity much greater than
that of DNA sequencing. The frequency of EGFR mutations in the present study was similar to …

… EGFR gene-sensitive mutations? J … epidermal growth factor receptor-tyrosine kinase inhibitors
in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor …

… inhibitors (TKIs; gefitinib and erlotinib) has been demonstrated in patients with non-small
cell lung cancers (NSCLC) harboring EGFR sensitive … found in squamous cell carcinoma (SCC) …

… sensitivity to EGFR TKI inhibitors such that low-level EGFR tumours can be more sensitive
than tumours with high receptor … in patients with advanced squamous cell carcinoma of the …

… in the squamous … sensitive amplification refractory mutation system.9, 12 The relatively low
level of mutations in these populations, in which mutations were detected by highly sensitive …

… molecule tyrosine kinase inhibitors (… Sensitivity to gefitinib in a panel of 18 squamous cell
carcinoma of the head and neck (SCCHN) cell lines. (A) There is a 500-fold range in sensitivity …

… epidermal growth factor receptor tyrosine kinase inhibitor … -line epidermal growth factor
receptor tyrosine kinase inhibitor … Although the results from more recent trials using more sensitive …

… Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently … lung
cancer (NSCLC) harboring EGFR-sensitive mutations. The majority of clinical data regarding …

Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …